An Immunotolerant HER-2/neuTransgenic Mouse Model of Metastatic Breast Cancer
- 30 September 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (19), 6116-6124
- https://doi.org/10.1158/1078-0432.ccr-07-4672
Abstract
Purpose: Animal models of breast cancer metastases that recapitulate the pattern of metastatic progression seen in patients are lacking; metastatic breast cancer models do not currently exist for evaluation of immune-mediated therapies. We have developed and characterized a preclinical model for the evaluation of immune-mediated metastatic breast cancer therapies. Experimental Design: The NT2.5 mammary tumor cell line was injected into the left cardiac ventricle of immunotolerant transgenic neu-N mice and athymic nu/nu mice. Metastatic progression was monitored by bioluminescent, small-animal magnetic resonance imaging, positron emission tomography, single-photon emission computed tomography/computed tomography imaging, and also by histopathology. Antigen expression in normal organs and tumor metastases was evaluated by Western blot analysis and flow cytometry. Results: Left cardiac ventricle injection of NT2.5 cells yielded widespread metastases in bones, liver, and spleen. Three to four weeks after injection, mice exhibited hind limb paralysis and occasional abdominal enlargement. Bioluminescence imaging of metastatic progression was successful in nude mice but the bioluminescent cells were rejected in immunocompetent mice. Other imaging modalities allowed successful imaging of nonbioluminescent cells. Small-animal positron emission tomography imaging allowed visualization of disease, in vivo, in the bones and liver. Magnetic resonance imaging revealed initial dissemination of the tumor cells to the bone marrow. Small-animal single-photon emission computed tomography/computed tomography imaging identified metastatic bone lesions targeted by a radiolabeled antibody. Conclusion: The model closely recapitulates the pattern of metastatic spread in breast cancer. This immunotolerant metastatic model is a novel addition to existing breast cancer models and coupling the model with in vivo imaging greatly facilitates the evaluation of targeted immunotherapies of metastasis.Keywords
This publication has 44 references indexed in Scilit:
- 213Bi (α-Emitter)–Antibody Targeting of Breast Cancer Metastases in theneu-N Transgenic Mouse ModelCancer Research, 2008
- Metabolic Imaging by Hyperpolarized 13C Magnetic Resonance Imaging for In vivo Tumor DiagnosisCancer Research, 2006
- Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapyEuropean Journal Of Cancer, 2006
- Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapyNature Biotechnology, 2005
- The multiple uses of fluorescent proteins to visualize cancer in vivoNature Reviews Cancer, 2005
- A Mouse Model of Human Breast Cancer Metastasis to Human BoneCancer Research, 2005
- Molecular Imaging of Temporal Dynamics and Spatial Heterogeneity of Hypoxia-Inducible Factor-1 Signal Transduction Activity in Tumors in Living MiceCancer Research, 2004
- Somatic Mutation of p53 Leads to Estrogen Receptor α-Positive and -Negative Mouse Mammary Tumors with High Frequency of MetastasisCancer Research, 2004
- Green fluorescent protein expression in dendritic cells enhances their immunogenicity and elicits specific cytotoxic T-cell responses in humansExperimental Hematology, 2004
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002